McDermott Will & Emery represented Applied DNA Sciences, Inc., while Harter Secrest & Emery represented the placement agent in the transaction. Applied DNA Sciences, Inc. (Applied...
Applied DNA Sciences’ $3.44 Million Shares Offering
Applied DNA’s Acquisition of Spindle Biotech
McDermott represented Applied DNA Sciences, Inc. in the transaction. Applied DNA Sciences, Inc. (“Applied DNA”), a leader in PCR-based DNA technologies, announced its acquisition of Spindle...
Inhibikase Therapeutics’ $10 Million Direct Offering and Private Placements
McDermott Will & Emery represented Inhibikase Therapeutics, Inc. in the transaction. Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the...
Spine Biopharma’s $13 Million Series B Equity Financing
McDermott Will & Emery represented Spine Biopharma in the transaction. Spine Biopharma, Inc, a biopharmaceutical company committed to developing non-opiate, non-surgical therapies for the treatment of...
PharmaCyte Biotech’s $15 Million Follow-On Public Offering
Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech, Inc. on the deal. PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer...
PharmaCyte’s $70 Million Rights Offering
Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech on the deal. PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and...
BioXcel Therapeutics’ $100 Million Public Offering
Troutman Pepper Hamilton Sanders LLP advised BioXcel LLC on the deal. BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, announced the pricing of an...
Inhibikase Therapeutics’ $45 Million Follow-On Public Offering
Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the...
Pacira Biosciences’ $3M Investment in Spine BioPharma
Troutman Pepper Hamilton Sanders LLP advised Spine BioPharma, LLC on the deal. Spine BioPharma, LLC, a company committed to developing non-surgical, non-opiate therapies to treat degenerative...